Quarterly report pursuant to Section 13 or 15(d)

Segment Information

Segment Information
9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Information Segment Information
ASC 280, Segment reporting, establishes annual and interim reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenue and incur expenses, and for which discrete financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources and assess performance.

We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our operating segments are identified in the same manner as they are reported internally and used by our chief operating decision maker for the purpose of evaluating performance and allocating resources. Historically, we have disclosed one reportable segment. On March 23, 2022, we entered into the Merger Agreement, pursuant to which APAC would combine with OmniAb, and acquire the OmniAb Business, in a Reverse Morris Trust transaction (collectively, the “Transactions”). Immediately prior to the Merger and pursuant to the Separation Agreement, we, among other things, would transfer the OmniAb Business, including but not limited to the equity interests of Ab Initio Biotherapeutics, Inc., Crystal Bioscience, Inc., Icagen, LLC, Taurus Biosciences, LLC and xCella Biosciences, Inc. to OmniAb (the “Reorganization”) and, in connection therewith, would distribute (the “Distribution”) to Ligand stockholders 100% of the common stock of OmniAb. Immediately following the Distribution, Merger Sub would merge with and into OmniAb (the “Merger”), with OmniAb continuing as the surviving company in the Merger and as a wholly owned subsidiary of APAC. The entire transaction was completed on November 1, 2022. See Note 9, Subsequent Event, for additional information.

In connection with the execution of the Merger Agreement, we made organizational changes to better align our organizational structure with our strategy and operations, and management has reorganized the reportable segments to better reflect how the business is evaluated by the chief operating decision maker. Beginning in the first quarter of 2022, we operated the following two reportable segments: (1) OmniAb business and (2) Ligand core business. The OmniAb business segment is focused on enabling the discovery of therapeutic candidates for our partners by pairing antibody repertoires generated from our proprietary transgenic animals with our OmniAb business platform screening tools. The Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. After the closing date of the Transactions, the historical financial results of OmniAb will be reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the Distribution.

Our chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income (loss) represents income (loss) before income taxes, interest income, interest expense, other income (expense), net, unallocated share-based compensation, and unallocated corporate overhead. Our management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
OmniAb business revenue
  Royalties $ 582  $ —  $ 984  $ — 
  Contract 6,285  5,140  22,353  19,520 
Total OmniAb business revenue
6,867  5,140  23,337  19,520 
Ligand core business revenue
  Royalties 19,255  15,648  50,507  $ 31,376 
  Captisol - Core 3,582  5,374  13,133  16,310 
  Captisol - COVID 32,367  29,719  64,483  112,565 
  Contract 4,017  8,954  17,740  24,889 
 Total Ligand core business revenue 59,221  59,695  145,863  185,140 
     Total revenue $ 66,088  $ 64,835  $ 169,200  $ 204,660 
Segment operating income (loss)
OmniAb business
$ (11,721) $ (9,177) $ (26,905) $ (21,587)
Ligand core business 22,022  32,620  49,050  112,601 
Total segment operating income 10,301  23,443  22,145  91,014 
Unallocated corporate items
Shared-based compensation 6,462  5,811  17,255  16,429 
Other corporate expenses 3,203  1,926  14,029  8,424 
  Total unallocated corporate items 9,665  7,737  31,284  24,853 
Income (loss) from operations $ 636  $ 15,706  $ (9,139) $ 66,161